{Reference Type}: Editorial
{Title}: A Plea for Economically Sustainable Evidence-based Guidelines.
{Author}: Martini A;Mottet N;Montorsi F;Necchi A;Ribal MJ;Malavaud B;
{Journal}: Eur Urol
{Volume}: 82
{Issue}: 5
{Year}: 11 2022
{Factor}: 24.267
{DOI}: 10.1016/j.eururo.2022.08.001
{Abstract}: The rising costs of cancer care with the introduction of new agents are a challenge. The impact of these costs differs among countries. We compare costs for metastatic prostate cancer, with prices normalized to international dollars, as an example that highlights the need for cost-effectiveness analyses in trials and treatment guidelines.